Author

A. Galbiati

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 3 Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:CRISPR screen· 1 Approach:genetic perturbation / CRISPR· 1 Assay:metabolomics· 1

Frequent Co-Authors

A. Zana· 2 shared D. Neri· 2 shared J. Millul· 2 shared S. Cazzamalli· 2 shared A. Cerutti· 1 shared A. Cicconi· 1 shared A. Elsayed· 1 shared D. Barrell· 1 shared

Activity by Year

2022-2022 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

A. Zana

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Small-molecule Polθ inhibitors provide safe and effective tumor radiosensitization in preclinical models

G. Rodriguez-Berriguete, M. Ranzani, R. Prevo, R. Puliyadi, N. Machado, H. R. Bolland, V. Millar, D. Ebner, M. Boursier, A. Cerutti, A. Cicconi, A. Galbiati, D. Grande, V. Grinkevich, J. Majithiya, , G. S. Higgins

This study shows that Polθ inhibitors ART558 and ART899 radiosensitize tumor cells without affecting normal fibroblasts, suggesting potential for safe cancer radiotherapy.

bioRxiv · Sep 27, 2022Cancer Biology

Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibition

K. Jamal, A. Galbiati, J. Armenia, G. Illuzzi, J. Hall, S. Bentouati, D. Barrell, M. Ahdesmäki, Functional Genomics Centre, M. J. O'Connor, E. Leo, J. V. Forment

The paper identifies 110 genes linked to PARP inhibitor sensitivity through CRISPR screens and tumor data analysis, highlighting XRCC3 as a potential biomarker for prostate cancer.

bioRxiv · Jul 29, 2022Cancer Biology

A mass spectrometry-based method for the determination of in vivo biodistribution of tumor targeting small molecule-metal conjugates

E. Gilardoni, A. Zana, A. Galbiati, T. Sturm, J. Millul, S. Cazzamalli, D. Neri, R. Stucchi

The paper develops a mass spectrometry-based method to quantify tumor-targeting small molecule-metal conjugates and validates it against radioactive biodistribution data.

bioRxiv · Mar 4, 2022Pharmacology & Toxicology

A novel dimeric FAP-targeting small molecule-radio conjugate with high and prolonged tumour uptake

A. Galbiati, A. Zana, M. Bocci, J. Millul, A. Elsayed, J. Mock, D. Neri, S. Cazzamalli

This paper develops a dimeric FAP-targeting radioligand with prolonged tumour uptake and improved tumour-to-organ ratio, showing potent anti-tumour efficacy in preclinical models.

bioRxiv · Feb 21, 2022Pharmacology & Toxicology